Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study
DOI:
https://doi.org/10.2340/actadv.v104.26002Keywords:
acne, spironolactone, adult female acne, AFAST, doxycycline, quality of lifeAbstract
Acne in adult females is triggered mainly by hormones. Doxycycline is a reference treatment in acne. Spironolactone targets the androgen receptor of sebaceous glands and is prescribed off-label for female adult acne. This multicentre, controlled, randomized, double-blind prospective and parallel study assessed the efficacy of spironolactone compared with doxycycline in adult female acne. A total of 133 women with moderate acne were randomized to receive treatment with: (i) doxycycline and benzoyl peroxide for 3 months followed by a 3-month treatment with its placebo and benzoyl peroxide, or (ii) spironolactone and benzoyl peroxide for 6 months. Successfully treated patients continued with benzoyl peroxide or spironolactone alone for a further 6 months. Primary endpoints were treatment success at month 4 and month 6 with the AFAST score. At all visits, the ECLA score, lesion counts, local and systemic safety and quality of life were assessed. Spironolactone performed better at month 4 and showed a statistically significant better treatment success after 6 months than doxycycline (p = 0.007). Spironolactone was 1.37-times and 2.87-times more successful compared with doxycycline at respective time-points. AFAST and ECLA scores, as well as lesion counts always improved more with spironolactone. Patients’ quality of life was better with spironolactone at month 4 and month 6. Spironolactone was very well tolerated. This is the first study to show that, in female adults with moderate acne, treatment with spironolactone is significantly more successful than doxycycline and very well tolerated.
Downloads
References
Preneau S, Dreno B. Female acne - a different subtype of teenager acne? J Eur Acad Dermatol Venereol 2012; 26: 277-282.
https://doi.org/10.1111/j.1468-3083.2011.04214.x DOI: https://doi.org/10.1111/j.1468-3083.2011.04214.x
Dreno B, Thiboutot D, Layton AM, Berson D, Perez M, Kang S. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol 2015; 29: 1096-1106.
https://doi.org/10.1111/jdv.12757 DOI: https://doi.org/10.1111/jdv.12757
Branisteanu DE, Toader MP, Porumb EA, Serban IL, Pinzariu AC, Branisteanu CI, et al. Adult female acne: Clinical and therapeutic particularities (Review). Exp Ther Med 2022; 23: 151. DOI: https://doi.org/10.3892/etm.2022.11184
https://doi.org/10.3892/etm.2021.11074 DOI: https://doi.org/10.3892/etm.2021.11074
Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001; 15: 541-545.
https://doi.org/10.1046/j.1468-3083.2001.00357.x DOI: https://doi.org/10.1046/j.1468-3083.2001.00357.x
Dréno B, Dagnelie MA, Khammari A, Corvec S. The skin microbiome: a new actor in inflammatory acne. Am J Clin Dermatol 2020; 21: 18-24.
https://doi.org/10.1007/s40257-020-00531-1 DOI: https://doi.org/10.1007/s40257-020-00531-1
Dreno B, Thiboutot D, Gollnick H, Bettoli V, Kang S, Leyden JJ, et al. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol 2014; 24: 330-334.
https://doi.org/10.1684/ejd.2014.2309 DOI: https://doi.org/10.1684/ejd.2014.2309
Castellanos Lorduy HJ, Pérez Cely HC, Casadiego Rincón EJ, Henao Riveros SC, Colorado CL. Cutibacterium acnes tetracycline resistance profile in patients with acne vulgaris, in a Colombian Dermatologic Center. Actas Dermosifiliogr (Engl Ed) 2021 May 19: S0001-7310(21)00191-5
Leclerc-Mercier S, Buisson V, Dreno B. New regulations for oral contraceptive prescription in France in 2013: what is the impact on adult female acne? Eur J Dermatol 2016; 26: 345-349.
https://doi.org/10.1684/ejd.2016.2773 DOI: https://doi.org/10.1684/ejd.2016.2773
Barbieri JS, Spaccarelli N, Margolis DJ, James WD. Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J Am Acad Dermatol 2019; 80: 538-549.
https://doi.org/10.1016/j.jaad.2018.09.055 DOI: https://doi.org/10.1016/j.jaad.2018.09.055
Moore A, Ling M, Bucko A, Manna V, Rueda MJ. Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study. J Drugs Dermatol 2015; 14: 581-586.
Nast A, Dreno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol 2016; 30: 1261-1268.
https://doi.org/10.1111/jdv.13776 DOI: https://doi.org/10.1111/jdv.13776
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74: 945-973.e33.
https://doi.org/10.1016/j.jaad.2015.12.037
[No authors listed] Spironolactone. Brit Med J 1967; 2: 751.
https://doi.org/10.1136/bmj.2.5554.751 DOI: https://doi.org/10.1136/bmj.2.5554.751
Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5 alpha-dihydrotestosterone in vitro. J Invest Dermatol 1993; 100: 660-662.
https://doi.org/10.1111/1523-1747.ep12472325 DOI: https://doi.org/10.1111/1523-1747.ep12472325
Han JJ, Faletsky A, Barbieri JS, Mostaghimi A. New acne therapies and updates on use of spironolactone and isotretinoin: a narrative review. Dermatol Ther 2021; 11: 79-91.
https://doi.org/10.1007/s13555-020-00481-w DOI: https://doi.org/10.1007/s13555-020-00481-w
Carmina E, Dreno B, Lucky WA, Agak WG, Dokras A, Kim JJ, et al. Female Adult acne and androgen excess: a report from the Multidisciplinary Androgen Excess and PCOS Committee. J Endocr Soc 2022; 6: bvac003.
https://doi.org/10.1210/jendso/bvac003 DOI: https://doi.org/10.1210/jendso/bvac003
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74: 945-973.e33.
https://doi.org/10.1016/j.jaad.2015.12.037 DOI: https://doi.org/10.1016/j.jaad.2015.12.037
Poinas A, Lemoigne M, Le Naour S, Nguyen JM, Schirr-Bonnans S, Riche VP, et al. FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial. Trials 2020; 21: 571.
https://doi.org/10.1186/s13063-020-04432-w DOI: https://doi.org/10.1186/s13063-020-04432-w
Auffret N, Claudel JP, Leccia MT, Poli F, Farhi D, Dréno B. AFAST - Adult Female Acne Scoring Tool: an easy-to-use tool for scoring acne in adult females. J Eur Acad Dermatol Venereol 2016; 30: 824-828.
https://doi.org/10.1111/jdv.13518 DOI: https://doi.org/10.1111/jdv.13518
Cooper DB, Patel P, Mahdy H. Oral contraceptive pills. Treasure Island, FL: StatPearls Publishing LLC, 2023.
Dreno B, Poli F, Pawin H, Beylot C, Faure M, Chivot M, et al. Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe. J Eur Acad Dermatol Venereol 2011; 25: 43-48.
https://doi.org/10.1111/j.1468-3083.2010.03685.x DOI: https://doi.org/10.1111/j.1468-3083.2010.03685.x
Dreno B, Bodokh I, Chivot M, Daniel F, Humbert P, Poli F, et al. La grille ECLA : un système de cotation de l'acné pour la pratique quotidienne du dermatologue. Ann Dermatol Venereol 1999; 126: 136-41.
Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol 1992; 17: 1-3.
https://doi.org/10.1111/j.1365-2230.1992.tb02521.x DOI: https://doi.org/10.1111/j.1365-2230.1992.tb02521.x
Balestroni G, Bertolotti G. [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis 2012; 78: 155-159 (in Italian).
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol 2017; 18: 169-191.
https://doi.org/10.1007/s40257-016-0245-x DOI: https://doi.org/10.1007/s40257-016-0245-x
Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol 2017; 18: 469-490.
https://doi.org/10.1007/s40257-017-0267-z DOI: https://doi.org/10.1007/s40257-017-0267-z
Isvy-Joubert A, Nguyen JM, Gaultier A, Saint-Jean M, Le Moigne M, Boisrobert E, et al. Adult female acne treated with spironolactone: a retrospective data review of 70 cases. Eur J Dermatol 2017; 27: 393-398.
https://doi.org/10.1684/ejd.2017.3062 DOI: https://doi.org/10.1684/ejd.2017.3062
Wang Y, Lipner SR. Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration. Int J Womens Dermatol 2020; 6: 272-276.
https://doi.org/10.1016/j.ijwd.2020.05.002 DOI: https://doi.org/10.1016/j.ijwd.2020.05.002
Basu P, Elman SA, Abudu B, Beckles A, Salian P, Yanes DA, et al. High-dose spironolactone for acne in patients with polycystic ovarian syndrome: a single-institution retrospective study. J Am Acad Dermatol 2021; 85: 740-741.
https://doi.org/10.1016/j.jaad.2019.07.102 DOI: https://doi.org/10.1016/j.jaad.2019.07.102
Saint-Jean M, Ballanger F, Nguyen JM, Khammari A, Dreno B. Importance of spironolactone in the treatment of acne in adult women. J Eur Acad Dermatol Venereol 2011; 25: 1480-1481.
https://doi.org/10.1111/j.1468-3083.2010.03926.x DOI: https://doi.org/10.1111/j.1468-3083.2010.03926.x
Published
How to Cite
License
Copyright (c) 2024 Brigitte Dréno, Jean-Michel Nguyen, Ewa Hainaut, Laurent Machet, Marie-Thérèse Leccia, Nathalie Beneton, Jean-Paul Claudel, Philippe Célérier, Marie Le Moigne, Sarah Le Naour, Florence Vrignaud, Alexandra Poinas, Cécile Dert, Aurélie Boisrobert, Laurent Flet, Simon Korner, Amir Khammari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
